Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.

Saved in:
Bibliographic Details
Title: Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.
Authors: Ghia P; Università Vita-Salute San Raffaele, Milano, Italy; Comprehensive Cancer Center, IRCCS Ospedale San Raffaele, Milano, Italy. Electronic address: ghia.paolo@hsr.it., Rossi D; Clinic of Hematology, Oncology Institute of Southern Svitzerland, Ente Opsedaliero Cantonale and Institute of Oncology Research, Università della Svizzera italiana, Bellinzona, Switzerland., Ferrant E; Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie Clinique, Pierre-Bénite, France., de la Cruz Vicente F; Hospital Universitario Virgen del Rocío, Sevilla, Spain., Maruyama D; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Banerji V; Departments of Internal Medicine and Biochemistry & Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba and the Paul Albrechtsen Research Institute CancerCare Manitoba, Winnipeg, Manitoba, Canada., Cobb P; Intermountain Health Cancer Centers of Montana, Billings, Montana, Bulgaria., Namburi S; Swedish Cancer Institute, Seattle, WA, USA., Greil R; Paracelsus Medical University, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials; Cancer Cluster Salzburg, Austria., Sharman JP; Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USA., Hess LM; Eli Lilly and Company, Indianapolis, IN, USA., Payakachat N; Eli Lilly and Company, Indianapolis, IN, USA., Bhandari NR; Eli Lilly and Company, Indianapolis, IN, USA., Ruppert AS; Eli Lilly and Company, Indianapolis, IN, USA., Wang D; Eli Lilly and Company, Indianapolis, IN, USA., Abada P; Eli Lilly and Company, Indianapolis, IN, USA., Loubert A; Modus Outcomes, Lyon, France., Creel K; Modus Outcomes, Lyon, France., Qiao C; Eli Lilly and Company, Indianapolis, IN, USA., Han Y; Eli Lilly and Company, Indianapolis, IN, USA., Hill M; Eli Lilly and Company, Indianapolis, IN, USA., Leow CC; Eli Lilly and Company, Indianapolis, IN, USA., Coombs CC; University of California Irvine, Irvine, CA, USA., Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Source: Journal of geriatric oncology [J Geriatr Oncol] 2026 Jun 17; Vol. 17 (6), pp. 103024. Date of Electronic Publication: 2026 Jun 17.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101534770 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-4076 (Electronic) Linking ISSN: 18794068 NLM ISO Abbreviation: J Geriatr Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-4076
DOI:10.1016/j.jgo.2026.103024